The Trump Administration proposed new rules for pharmacy benefits managers promises to save Americans billions of dollars thanks to lower prices for prescription drugs, according to Eli Lilly CEO David Ricks, writing in an op-ed for USA Today.
- The proposed rule would require rebates from pharmaceutical companies to health insurance plans for brand name prescription drugs to be passed on to customers with upfront discounts at the pharmacy.
- The rule would affect seniors and low-income Americans on Medicare and Medicaid, but Trump hopes to extend the rule to all Americans with private insurance.
- Of particular concern are Americans with high-deductible insurance plans, which require their subscribers to pay thousands of dollars out of pocket before they reach their deductible threshold.
- Ricks gave an example of a typical Medicare Part D consumer, a diabetic whose costs for Humalog insulin would fall from $193 per month currently to just $64 under the new proposed pharmacy benefits managers rule.